Jun 29 – Jul 5, 2026 · 4 new studies, 3 reviews · Orthopaedic Oncology archive · All weeks
The new Orthopaedic Oncology research The Reduction sent the week of Jun 29 – Jul 5, 2026, with the week’s most recent reviews, each with a one-line summary.
Get papers like these by email, free: subscribe to The Reduction, focused on your interests, on the days you pick.
LL-37 peptide inhibits osteosarcoma through PTEN/AKT/mTOR pathway targeting cholesterol synthesis, offering promising therapeutic potential.
Phosphaturic mesenchymal tumors can present in atypical locations like fingers without tumor-induced osteomalacia; immunohistochemistry confirms diagnosis and marginal excision prevents recurrence.
Frailty is a Vital Tool for Predicting Outcomes Following Prophylactic Femur Fixation.
Preoperative frailty, particularly the revised Risk Analysis Index, independently predicts mortality and morbidity in patients undergoing prophylactic femur fixation.
Decompression with intraoperative vertebroplasty safely treated aggressive vertebral hemangiomas with reduced blood loss and low recurrence.
The role of molecular pathology in soft tissue tumor diagnosis: what the radiologist needs to know.
Molecular pathology enhances soft tissue sarcoma diagnosis and classification; MRI correlation guides clinicians on genetic testing.
Megavoltage radiotherapy reduced malignant transformation risk in giant cell tumors 8-fold compared with orthovoltage, supporting modern RT for inoperable cases.
Separation surgery for metastatic epidural spinal cord compression: A qualitative review.
Separation surgery combined with stereotactic body radiation therapy for metastatic epidural cord compression achieves good local control while reducing surgical morbidity.
← Week of Jun 22–28, 2026Week of Jul 6–12, 2026 →
Home · All weeks · Archive · Subscribe · FAQ
© 2026 The Reduction